{"id":"medi3250","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By bridging PD-L1 expressing tumors with 4-1BB on T cells, MEDI3250 blocks the PD-L1/PD-1 inhibitory axis while providing costimulatory 4-1BB signaling. This dual mechanism aims to overcome immune checkpoint suppression and amplify T cell activation and proliferation within the tumor microenvironment.","oneSentence":"MEDI3250 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:31.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT02269475","phase":"PHASE3","title":"A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-10","conditions":"Healthy Japanese Children Age 7 Years Through 18 Years","enrollment":1369},{"nctId":"NCT02269488","phase":"PHASE3","title":"A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11","conditions":"Healthy Japanese Children Age 2 Years Through 6 Years","enrollment":100},{"nctId":"NCT00860067","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-03","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT01091246","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-03","conditions":"Healthy or Stable Chronic Illness","enrollment":2312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MEDI3250","genericName":"MEDI3250","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MEDI3250 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in clinical development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}